TELA Bio, Inc. TELA

Moby summary of TELA Bio, Inc.'s Q2 2026 earnings call

TELA Bio (TELA) delivered earnings and revenue surprises of -17.65% and -3.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MALVERN, Pa., Aug. 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Announced appointment of Heather Getz as Chief Executive Officer and Director, effective August 4, 2026;Delivered international revenue growth of 26% over the prior year period, with continued momentum in several

MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 2,370,000 shares of its common stock and restricted stock units covering 500,000 shares of its common stock to the Company’s newly-hired Chief Executive Officer, He

MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors (the “Board”) has appointed Heather Getz as Chief Executive Officer and Director, effective today. “As TELA Bio enters its next phase of growth and commercial execution, the Board is pleased to welcome Heather as our next Chief Executive Officer,” said

MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 46th Annual Growth Conference. TELA’s management is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference at 8:30 am ET on August 12th, 2026. Interested parties can access the live and archived w

MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2026 financial results on Monday, August 10, 2026. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Second Quarter Earnings Confe

TELA Bio, Inc. ( NASDAQ:TELA ) shareholders are probably feeling a little disappointed, since its shares fell 10.0% to...

Moby summary of TELA Bio, Inc.'s Q1 2026 earnings call

Despite challenges in the U.S. market, TELA Bio Inc (TELA) reports significant revenue growth and strategic advancements in its product portfolio.

MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Announced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting on June 9, 2026;Noted the U.S. commercial organization is fully staffed at planned 2026 levels;Delivered reve

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -19.32% and +8.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?